Autonomic dysfunction in different subtypes of multiple system atrophy

Movement Disorders

Volumn 23, Issue 12, 2008, Pages 1766-1772

  Schmidt, Claudia ^a   Herting, Birgit ^a   Prieur, Silke ^a   Junghanns, Susann ^a   Schweitzer, Katherine ^b   Globas, Christoph ^b   Schöls, Ludger ^b   Reichmann, Heinz ^a   Berg, Daniela ^b   Ziemssen, Tjalf ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Autonomic dysfunction; Autonomic nervous system; MSA subtypes; Multiple system atrophy

Indexed keywords

AMANTADINE; BROMOCRIPTINE; CABERGOLINE; CATECHOL METHYLTRANSFERASE INHIBITOR; DIHYDROERGOCRYPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE;

ADULT; ARTICLE; AUTONOMIC DYSFUNCTION; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; MALE; NEUROLOGIC EXAMINATION; PARKINSONISM; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; QUESTIONNAIRE; SHY DRAGER SYNDROME; SLEEP DISORDER; UROGENITAL TRACT DISEASE; VASOMOTOR DISORDER;

EID: 55349095513     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22187     Document Type: Article

References (19)

1. Geser F, Wenning GK. The diagnosis of multiple system atrophy. J Neurol 2006;253 (Suppl 3):iii2-iii15.
2. Wenning GK, Geser F. Multiple system atrophy. Rev Neurol 2003;159(5, Part 2):3S31-3S38.
3. Jellinger KA, Seppi K, Wenning GK. Grading of neuropathology in multiple system atrophy: proposal for a novel scale. Mov Disord 2005;20 (Suppl 12):S29-S36.
4. da Rocha AJ, Maia AC, Jr, da Silva CJ, et al. Pyramidal tract degeneration in multiple system atrophy: the relevance of magnetization transfer imaging. Mov Disord 2007;22:238-244.
5. Schulz JB, Klockgether T, Petersen D, et al. Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT. J Neurol Neurosurg Psychiatr 1994;57:1047-1056.
6. Taniwaki T, Nakagawa M, Yamada T, et al. Cerebral metabolic changes in early multiple system atrophy: a PET study. J Neurol Sci 2002;200:79-84.
7. Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Auton Nerv Syst 1998; 74:189-192.
8. Schmidt C, Herting B, Prieur S, et al. Pupil diameter in darkness differentiates progressive supranuclear palsy (PSP) from other extrapyramidal syndromes. Mov Disord 2007;22:2123-2126.
9. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Neurology 1996;46:1470.
10. Ozawa T. Morphological substrate of autonomic failure and neurohormonal dysfunction in multiple system atrophy: impact on determining phenotype spectrum. Acta Neuropathol (Berl) 2007; 114:201-211.
11. Oppenheimer DR. Lateral horn cells in progressive autonomic failure. J Neurol Sci 1980;46:393-404.
12. Ozawa T, Paviour D, Quinn NP, et al. The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain 2004;127(Part 12):2657-2671.
13. Abdo WF, van de Warrenburg BP, Kremer HP, Bloem BR, Verbeek MM. CSF biomarker profiles do not differentiate between the cerebellar and parkinsonian phenotypes of multiple system atrophy. Parkinsonism Relat Disord 2007;13:480-482.
14. Magnificio F, Misra VP, Murray NMF, Mathias CJ. The laboratory detection of autonomic dysfuntion in multiple system atrophy - the role of the sympathetic skin response. Neurology 1997; 48 (Suppl):A190.
15. Goldstein DS. Dysautonomia in Parkinson's disease: neurocardiological abnormalities. Lancet Neurol 2003;2:669-676.
16. Jost WH. [Autonomic dysregulations in Parkinson's syndrome]. Schweizerische Rundschau Medizin Praxis = Rev Suisse Med PRAXIS 2005;94:1639-1646.
17. Mesec A, Sega S, Kiauta T. The influence of the type, duration, severity and levodopa treatment of Parkinson's disease on cardiovascular autonomic responses. Clin Auton Res 1993;3:339-344.
18. Bouhaddi M, Vuillier F, Fortrat JO, et al. Impaired cardiovascular autonomic control in newly and long-term-treated patients with Parkinson's disease: involvement of L-dopa therapy. Auton Neurosci 2004;116:30-38.
19. Senard JM, Verwaerde P, Rascol O, Montastruc JL. Effects of acute levodopa administration on blood pressure and heart variability in never treated parkinsonians. Hypertens Res 1995;18 (Suppl 1):S175-S177.